Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
Sign Up to like & getrecommendations! Published in 2023 at "Circulation Research"
DOI: 10.1161/circresaha.122.321504
Abstract: Background: The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance analysis of Food and Drug Administration and World Health Organization datasets has revealed that… read more here.
Keywords: inflammation; ponatinib drives; drives cardiotoxicity; ponatinib ... See more keywords